December 20, 2007
RNL BIO CO. LTD.,(KSE: 003190), a premier Korean biotechnology company dedicated to the development of stem cell based therapeutics to treat various degenerative and obstinate diseases, announced today that Korean Food and Drug Administration approved its first Investigational New Drug application for the treatment of Buerger’s disease. VascostemTM, the company’s first stem cell product prepared from ex vivo expansion of patients’ own fat tissue, will be evaluated for 16 patients at Kang-Nam St. Mary’s Hospital in Seoul, Korea.
“This is the first clinical application of our long-developed adult stem cells technology and autologous stem cell therapy is free from any ethical controversies and side effects that are typically associated with artificial materials or immune rejections from certain allogeneic stem cell therapies,” said Dr. Jeong Chan Ra, President and CEO of RNL Bio.
Buerger's Disease is a rare inflammatory and blood-clotting condition that hits heavy smokers, obstructing blood flow to their hands and feet. There is no known conservative cure for this indication and amputation is the final decision.
12/20/2007
12/14/2007
First Commercial Drug Sniffing Dog Cloning by South Korea
http://www.cosmosmagazine.com/node/1448
http://www.reuters.com/article/latestCrisis/idUSSEO273798
Korean Custom sponsored Seoul National University for the cloning project of their valuable drug sniffing dog. Last month, seven healthy cloned dogs were born. Two of them were adapted by the agency and started to be trained as professional drug sniffers.
http://www.reuters.com/article/latestCrisis/idUSSEO273798
Korean Custom sponsored Seoul National University for the cloning project of their valuable drug sniffing dog. Last month, seven healthy cloned dogs were born. Two of them were adapted by the agency and started to be trained as professional drug sniffers.
Subscribe to:
Comments (Atom)